Tenofovir Disoproxil Industry Forecasted for Rapid Expansion, Reaching $4.86 Billion by 2030

The Business Research Company’s 2026 market reports introduce new features such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, all designed to enhance the depth, usability, and strategic value of the insights provided.

What Is the Current Market Size and Growth Rate of the Tenosynovitis Drugs Market?
The tenofovir disoproxil market size has grown strongly in recent years. It will grow from $3.76 billion in 2025 to $3.96 billion in 2026 at a compound annual growth rate (CAGR) of 5.3%. The growth in the historic period can be attributed to high global hiv prevalence, expansion of antiretroviral therapy programs, inclusion in first-line treatment guidelines, growth in hepatitis b diagnosis, donor-funded antiviral access programs.

The tenofovir disoproxil market size is expected to see strong growth in the next few years. It will grow to $4.86 billion in 2030 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to rising demand for chronic viral management, expansion of generic antiviral production, increasing healthcare access in emerging markets, growth in preventive antiviral use, sustained public health funding. Major trends in the forecast period include rising demand for antiviral combination therapies, increased use in hiv and hepatitis b management, growing adoption of fixed-dose combinations, expansion of long-term antiviral treatment, increased focus on viral suppression strategies.

Claim your free report sample now:
https://www.thebusinessresearchcompany.com/report/tenofovir-disoproxil-global-market-report

What Are the Major Drivers Influencing the Tenofovir Disoproxil Market?
The growing prevalence of hepatitis B is expected to fuel the growth of the tenofovir disoproxil market going forward. Hepatitis B is a viral infection that attacks the liver, potentially causing both acute and chronic disease, and is transmitted through contact with infected blood or bodily fluids. The growing prevalence of hepatitis B is driven by factors such as perinatal transmission, unsafe medical practices, lack of vaccination coverage, and the persistence of chronic infections in affected populations. Tenofovir disoproxil is used in the treatment of chronic hepatitis B to suppress viral replication and reduce liver damage. For instance, in March 2023, according to a report published by the Centers for Disease Control and Prevention, a US-based government agency for protecting public health, in the United States, an estimated 580,000 to 2.4 million people are living with hepatitis B infection, with about two-thirds potentially unaware of their condition. Therefore, the growing prevalence of hepatitis B is driving the growth of the tenofovir disoproxil market.

What Segment Categories Define the Tenofovir Disoproxil Market Structure?
The tenofovir disoproxil market covered in this report is segmented –

1) By Type: Tablet, Powder
2) By Distribution Channel: Online Pharmacies, Retail Pharmacies, Wholesalers Or Distributors
3) By Application: Hospital, Clinic

Subsegments:
1) By Tablet: Single-Drug Tablets, Fixed-Dose Combination Tablets
2) By Powder: Oral Powder, Reconstitutable Powder

Which Emerging Trends Are Driving the Tenofovir Disoproxil Market?
Major companies operating in the tenofovir disoproxil market are focusing on expanding access via international quality certified formulations, such as WHO prequalified tablets, to reach global HIV and hepatitis B patient populations. A WHO prequalified tenofovir disoproxil fumarate tablet meets rigorous global standards for quality, safety, and efficacy, enabling broader distribution in resource limited settings. For instance, in August 2024, Shijiazhuang Lonzeal Pharmaceuticals Co., Ltd., a China based pharmaceutical company, achieved WHO prequalification for its 300 mg tenofovir disoproxil fumarate 300 mg film coated tablet (Product code HP030), with demonstrated bioequivalence, GMP certification, and acceptability for HIV treatment. Therefore, global quality certified supply is driving the growth of the tenofovir disoproxil market.

Which Are the Top Companies in the Tenofovir Disoproxil Market?
Major companies operating in the tenofovir disoproxil market are Gilead Sciences Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Cipla Ltd., Lupin Limited, Mylan N.V., Qilu Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Limited, Hetero Drugs Limited, Laurus Labs Limited, Zydus Lifesciences Ltd., Blanver, SMS Pharmaceuticals, Bajaj Healthcare, Mangalam Drugs & Organics Ltd., Arene Lifesciences, Aurisco Pharmaceutical Co. Ltd., Sinoway Industrial Co. Ltd.

Get the full tenofovir disoproxil market report here:
https://www.thebusinessresearchcompany.com/report/tenofovir-disoproxil-global-market-report

How does the Tenofovir Disoproxil Market perform across different regions?
North America was the largest region in the tenofovir disoproxil market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tenofovir disoproxil market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Contact Us:

The Business Research Company: Global Market Research Reports & Consulting | The Business Research Company
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info

Follow Us On:

LinkedIn: The Business Research Company | LinkedIn